Abstract Background and Aims Vedolizumab is a gut-selective antibody to α 4 β 7 integrin,
approved to treat moderate-to-severe ulcerative colitis and Crohn's disease in adults …

Background Vedolizumab, a gut‐selective α4β7 integrin antibody, is approved for
moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD). Aim To report …

Abstract Background & Aims Vedolizumab is an anti-a4b7 monoclonal antibody that is
licensed for the treatment of moderate to severe Crohn's disease and ulcerative colitis. The …

Objective Vedolizumab is a gut-selective antibody to α4β7 integrin for the treatment of
ulcerative colitis (UC) and Crohn's disease (CD). We report an integrated summary of the …

Abstract Background and Aims: The GEMINI long-term safety [LTS] study is a continuing
phase 3 trial investigating the safety and efficacy of vedolizumab, an α4β7 integrin …

Abstract Background and Aims: Vedolizumab is a gut-selective α4β7 integrin antagonist
therapy for ulcerative colitis and Crohn's disease. The GEMINI long-term safety [LTS] trial is …

Background & Aims There are few real-world data on the safety of vedolizumab for treatment
of Crohn's disease (CD) or ulcerative colitis (UC). We quantified rates and identified factors …

Introduction The efficacy and safety of vedolizumab, a gut-selective α 4 β 7 integrin antibody,
were demonstrated in the GEMINI 1 and GEMINI 2 clinical trials of adults aged 18–80 years …

Background Vedolizumab, a gut-selective, anti-inflammatory monoclonal antibody, has
shown preliminary efficacy in ulcerative colitis (UC) and Crohn's disease (CD). We report …

Background The efficacy and safety of vedolizumab in bio-naïve patients with ulcerative
colitis (UC) and Crohn's disease (CD) remain unknown. Aims To perform a meta-analysis …